PatientsHCP
This site is for US Health Care Professionals only.

ENTRESTO® is designed specifically to treat heart failure (HF)1-3 

ENTRESTO has a dual MOA that targets 2 complementary HF pathways1-3 
Graphic showing the dual mechanism of action of Entresto. Valsartan, RAS inhibition: decreased vasoconstriction, reduced sodium and water retention, and reduced hypertrophy and fibrosis. Sacubitril, Neprilysin inhibition: increased vasodilation, increased natriuresis/diuresis, reduced hypertrophy and fibrosis.

Blocking 1 pathway with ACEi/ARB is not enough

Discover support and resources to help your patients start on ENTRESTO

GET SUPPORT & RESOURCES

View ENTRESTO clinical and biomarker data for HFrEF

REVIEW THE DATA
*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1

Definitions  
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; MOA, mechanism of action; RAS, renin-angiotensin system. 

References 
1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
2. Hasenfuss G, Mann DL. Pathophysiology of heart failure. In: Mann DL, Zipes DP, Libby P, Bonow RO, eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Elsevier Saunders; 2015:1-116. 
3. Hilal-Dandan R. Renin and angiotensin. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. McGraw-Hill; 2011:721-744.